Denali Therapeutics Inc. Common Stock (DNLI) Stock Price

DNLIStock

$24.93+56.23%52W

Market Cap$3.98B

P/E—

PEG Ratio—

Div yield—

Beta1.00

DNLI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.60%

Price vs S&P 500 (4W)-2.43%

VGM Score41.78

Book Value / Share (Quarterly)$5.23

P/TBV (Annual)2.44x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.92

Price vs S&P 500 (YTD)34.62%

Net Profit Margin (TTM)-3539.21%

EPS (TTM)$-2.84

10-Day Avg Trading Volume1.11M

EPS Excl Extra (TTM)$-2.84

EPS (Annual)$-2.97

ROI (Annual)-50.28%

Net Profit Margin (5Y Avg)-332.00%

Cash / Share (Quarterly)$4.45

ROA (Last FY)-44.77%

EBITD / Share (TTM)$-2.94

ROE (5Y Avg)-32.10%

Operating Margin (TTM)-3622.11%

Cash Flow / Share (Annual)$-2.70

P/B Ratio4.85x

P/B Ratio (Quarterly)4.89x

Net Income / Employee (Annual)$-1,019,000

EV / Revenue (TTM)1069.53x

Net Interest Coverage (TTM)-167.00x

ROA (TTM)-44.24%

EV / EBITDA (TTM)113.04x

EPS Incl Extra (Annual)$-2.97

Current Ratio (Annual)9.16x

Quick Ratio (Quarterly)7.93x

3-Month Avg Trading Volume1.73M

52-Week Price Return56.23%

Revenue / Employee (TTM)$7,200

Tangible BV / Share (Quarterly)$5.01

P/S Ratio (Annual)12.25x

Asset Turnover (Annual)0.29x

52-Week High$27.30

Operating Margin (5Y Avg)-352.15%

EPS Excl Extra (Annual)$-2.97

CapEx CAGR (5Y)25.11%

Tangible BV CAGR (5Y)17.48%

26-Week Price Return25.84%

Quick Ratio (Annual)8.85x

13-Week Price Return25.39%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)8.37x

Enterprise Value$3.85B

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-7.43%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-43.93%

Cash / Share (Annual)$5.56

3-Month Return Std Dev51.67%

Net Income / Employee (TTM)$-1,016,800

ROE (Last FY)-50.56%

EPS Basic Excl Extra (Annual)$-2.97

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-2.84

Receivables Turnover (Annual)152.00x

ROI (TTM)-54.94%

P/S Ratio (TTM)1123.90x

Pretax Margin (5Y Avg)-332.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.67

Price vs S&P 500 (52W)37.92%

Year-to-Date Return46.58%

5-Day Price Return-0.45%

EPS Normalized (Annual)$-2.97

ROA (5Y Avg)-26.23%

Net Profit Margin (Annual)-43.94%

Month-to-Date Return5.13%

Cash Flow / Share (TTM)$-0.77

EBITD / Share (Annual)$-3.13

Operating Margin (Annual)-59.51%

ROI (5Y Avg)-31.99%

EPS Basic Excl Extra (TTM)$-2.84

P/TBV (Quarterly)5.10x

P/B Ratio (Annual)2.54x

Pretax Margin (TTM)-3539.21%

Book Value / Share (Annual)$6.49

Price vs S&P 500 (13W)22.59%

Beta1.00x

P/FCF (Annual)9.81x

Revenue / Share (TTM)$0.02

ROE (TTM)-55.27%

52-Week Low$12.58

vGradeF

mGradeB

vgmGradeC

DNLI Earnings Surprise History

Q2 25-0.72est. -0.74

Q3 25-0.74est. -0.76

Q4 25-0.73est. -0.75

Q1 26-0.69est. -0.71

Q2 26-0.68est. -0.47

DNLI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.36

4.35

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Denali Therapeutics Inc. Common Stock

Denali Therapeutics is a biotechnology company developing therapeutics for neurodegenerative diseases, with a lead program targeting LRRK2 inhibition for Parkinson's disease. Its pipeline includes multiple candidates leveraging proprietary delivery technologies, including antibody and enzyme transport vehicles designed to penetrate the blood-brain barrier.